Researchers say anastrozole may be as effective, if not more effective, than tamoxifen when it comes to treating DCIS. A study conducted by NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP) monitored DCIS patients taking anastrozole and patients taking tamoxifen for 5 years. Women under the age of 60 taking anastrozole had a slightly higher rate of dissease-free survival than those taking tamoxifen.
Of those women participating in the study, 88.8 percent who took anastrozole remained disease-free compared with 81.5 percent of those who received tamoxifen. Also according to the study, anastrozole demonstrated a favorable safety profile. There were 17 instances of uterine cancer in the tamoxifen group and 8 cases in the anastrozole group, although there were more occurrences of osteopathic fractures with anastrozole (69 events) than with tamoxifen (50 events).
To read the complete article on this study, click here.